Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13778292 | 0.81 | CYP11B1 (0.51) | CYP2A6TRPA1TDO2MAPK14NPC1 | |
| SCHEMBL13778315 | 0.81 | CYP2A6 (0.47) | CYP2A6TRPA1TDO2NPC1RAB9A | |
| SCHEMBL4446246 | 0.81 | CYP2A6 (0.47) | CYP2A6TDO2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3399384 | 0.81 | LCK (0.46) | TRPA1CHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5109073 | 0.81 | CYP2A6 (0.51) | CYP2A6TRPA1CHRNB1CHRNB2CHRNB4 | |
| SCHEMBL21364096 | 0.79 | ALOX5AP (0.41) | CYP2A6TRPA1CHRNB1CHRNB2CHRNB4 | |
| SCHEMBL18541115 | 0.78 | CYP2A6 (0.53) | CYP2A6TDO2CYP11B1CYP11B2 | |
| SCHEMBL23487641 | 0.78 | CYP2A6 (0.45) | CYP2A6TDO2ALPLCYP11B1CYP11B2 | |
| SCHEMBL16805019 | 0.78 | CHRNB1 (0.45) | CYP2A6CHRNB1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13870160 | 0.78 | HTR7 (0.45) | CYP2A6TRPA1CHRNB1CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-8053095-B2 | Compound comprising phenyl pyridine units | GENERAL ELECTRIC COMPANY (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20110121235-A1 | COMPOUND COMPRISING PHENYL PYRIDINE UNITS | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2011-05-26 | — | — | US | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110121235-A1 | COMPOUND COMPRISING PHENYL PYRIDINE UNITS | CRY1, C1S, C3AR1 | CYP2A6 217/4885TRPA1 88/4885CHRNB1 501/4885 |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | CYP2A6 1045/4885TRPA1 1301/4885CHRNB1 2619/4885 |
| US-20100197682-A1 | Organic Compounds | PIK3CA, PI4KA, PI4KB | CYP2A6 3866/4885TRPA1 3903/4885CHRNB1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.